^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    cyclophosphamide

    Company:
    Generic mfg.
    Drug class:
    Alkylating agent
    Related drugs:
    17h
    Engineered T-cell Therapy for Patients With ALPP-Positive Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=5, Terminated, TCRCure Biopharma Ltd. | N=24 --> 5 | Trial completion date: Aug 2027 --> Jan 2026 | Recruiting --> Terminated | Trial primary completion date: Aug 2026 --> Dec 2025; Portfolio prioritization
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • TC-A101
    17h
    Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes (clinicaltrials.gov)
    P2, N=50, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan • methotrexate IV
    19h
    UC02-123-01: Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies (clinicaltrials.gov)
    P1, N=32, Terminated, AvenCell Europe GmbH | N=90 --> 32 | Trial completion date: Sep 2025 --> Apr 2025 | Active, not recruiting --> Terminated; business decision by sponsor
    Enrollment change • Trial completion date • Trial termination
    |
    IL3RA (Interleukin 3 Receptor Subunit Alpha)
    |
    cyclophosphamide • fludarabine IV • AVC-101
    21h
    B7-H3.CD28Z.CART in Solid Tumors (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, Robbie Majzner
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV
    23h
    A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell Transplant (clinicaltrials.gov)
    P2, N=40, Recruiting, Memorial Sloan Kettering Cancer Center
    New P2 trial
    |
    Jakafi (ruxolitinib) • cyclophosphamide
    24h
    Addition of Venetoclax to Combined Hematopoietic Stem Cell and Kidney Transplantation (clinicaltrials.gov)
    P1, N=3, Not yet recruiting, Massachusetts General Hospital
    New P1 trial
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Venclexta (venetoclax) • cyclophosphamide • fludarabine IV
    1d
    Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer (clinicaltrials.gov)
    P2, N=120, Not yet recruiting, National Cancer Institute, Egypt
    New P2 trial
    |
    cyclophosphamide • etoposide IV
    1d
    QUADvance: Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies (clinicaltrials.gov)
    P1/2, N=178, Recruiting, AvenCell Therapeutics, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cyclophosphamide • fludarabine IV
    1d
    A Clinical Study on the Efficacy and Safety of All-trans Retinoic Acid Combined With VAC Regimen in the Treatment of Intermediate-to-high-risk Rhabdomyosarcoma (clinicaltrials.gov)
    P2, N=106, Not yet recruiting, Fudan University
    New P2 trial
    |
    Focus V (anlotinib) • cyclophosphamide
    1d
    DNADalHR: ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (clinicaltrials.gov)
    P2, N=393, Recruiting, Peking University People's Hospital | Not yet recruiting --> Recruiting
    Enrollment open • Circulating tumor DNA
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    ER positive • HR positive • HER-2 negative • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
    |
    paclitaxel • docetaxel • cyclophosphamide • exemestane • AiRuiKang (dalpiciclib)
    1d
    HV-101 for Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=1, Terminated, Hervor Therapeutics | N=18 --> 1 | Recruiting --> Terminated; Portfolio prioritization
    Enrollment change • Trial termination
    |
    cyclophosphamide • fludarabine IV • HV-101
    2d
    Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03) (clinicaltrials.gov)
    P3, N=764, Recruiting, Fudan University | N=548 --> 764
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    albumin-bound paclitaxel • cyclophosphamide